The pharma industry in Asia faces a challenge: a lack of standardisation in risk management planning is playing havoc with attempts to improve drug safety. Many nations in the Asia region are implementing their own national risk management schemes, but a lack of harmony between reporting threatens the collection of reports between countries.
Read about these and other challenges plus how the industry is confronting in its attempts to create a safer, more intelligent pharmacovigilance environment in Asia
Download PDF Attachment